RBC Capital raised the firm’s price target on CG Oncology (CGON) to $73 from $61 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $70 from $55 at Piper Sandler
- Oncolytics appoints John McAdory as EVP, strategy and operations
- CG Oncology Expands At-The-Market Equity Offering Capacity
- Biotech Alert: Searches spiking for these stocks today
- CG Oncology price target raised to $66 from $62 at Truist